As the hunt for skilled employees in China intensifies, pharmaceutical group Sanofi is using artificial intelligence to identify the most promising and loyal applicants.
“We are facing a very fierce talent war, not just from multinationals but from a lot of Chinese companies that want to expand,” says Iris Zhou, head of talent acquisition for Asia Pacific.
Sanofi has been using an algorithm for the past two years to assess interns on their potential cultural fit with the organisation. Only then are the shortlisted candidates interviewed by HR staff.
> Read the full article on the Financial Times website
By Andrew Jack
Source: Financial Times
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.